EMA transparency window 'ajar, not open', say campaigners
This article was originally published in SRA
Executive Summary
The European Medicines Agency may have furthered its efforts towards greater openness by publishing the minutes of three of its main scientific committees, but some critics say that the "transparency window" is not yet fully open, partly because of last year's legal challenges to the agency's policy of providing access to documents.